Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2022-04-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 11th meeting of the 8th Board of Directors of 普洛药业股份有限公司. It includes details about the approval of the 2022 Q1 report and changes in the board's professional committee members, including the resignation of an independent director and appointment of a new one. The document is a formal board meeting resolution announcement, not the full quarterly report itself. It also contains biographical information about the new director. This fits the category of Board/Management Information (MANG) as it announces changes in the company's board and management structure.
2022-04-26 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving a drug registration certificate from the national drug regulatory authority. It details the drug's specifications, approval, and potential impact on the company. The document is short (1109 characters) and serves as an official announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory filings related to financial performance. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category related to compliance and approvals, which aligns with Regulatory Filings (RNS).
2022-04-14 Chinese
2021年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the implementation of the 2021 annual equity distribution (dividend) plan of 普洛药业股份有限公司. It details the dividend amount per share, the record date, the ex-dividend date, the dividend recipients, and the method of dividend distribution. It also references the shareholders' meeting resolution approving the plan and provides contact information for inquiries. The document is short (1533 characters) and serves as an official announcement of the dividend payment details rather than the dividend declaration itself or a full financial report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-04-11 Chinese
关于左氧氟沙星片通过WHO的PQ认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the WHO PQ (prequalification) certification of a pharmaceutical product. It provides details about the product, its market impact, and a risk warning. The document is short (975 characters) and does not contain financial statements, audit information, or detailed financial data. It is an announcement of a certification event related to product approval and market impact, not a financial report or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, or Regulatory Filings. It is best classified as a general regulatory announcement about a significant company event, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2022-04-07 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2021 Annual General Meeting Resolution Announcement" for 普洛药业股份有限公司. It details the convening and attendance of the shareholders' meeting, voting results on various proposals including the 2021 annual report, board work report, financial statements, profit distribution plan, and amendments to company bylaws. The document includes voting percentages, legal opinions from lawyers, and confirmation of the meeting's legality. It does not contain the full annual report or financial statements themselves but reports on the resolutions passed at the AGM. The document length is 7266 characters, which is substantial but the content is clearly an announcement of voting results and resolutions from the AGM, not the full report or presentation materials. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-03-31 Chinese
2021年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2021 Annual General Meeting (AGM) of 普洛药业股份有限公司. It details the convening and holding procedures of the AGM, the qualifications of the convener and attendees, the voting procedures, and the voting results on various agenda items including approval of the 2021 annual report, board reports, financial statements, profit distribution plan, and amendments to company bylaws. The document does not contain the actual annual report or financial statements but rather provides a legal opinion on the legitimacy and compliance of the AGM process and voting results. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA) because it officially reports the voting outcomes of the shareholder meeting. The document length is sufficient and it is not merely an announcement of a report publication or a certification letter, so it is not RPA or RNS. Therefore, the best fitting category is DVA.
2022-03-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.